PMC:7113610 / 18942-19130 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"658","span":{"begin":0,"end":6},"obj":"Chemical"},{"id":"664","span":{"begin":164,"end":172},"obj":"Disease"},{"id":"665","span":{"begin":173,"end":182},"obj":"Disease"}],"attributes":[{"id":"A664","pred":"tao:has_database_id","subj":"664","obj":"MESH:C000657245"},{"id":"A665","pred":"tao:has_database_id","subj":"665","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of COVID-19 infection [55]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T197","span":{"begin":164,"end":172},"obj":"Disease"},{"id":"T198","span":{"begin":173,"end":182},"obj":"Disease"}],"attributes":[{"id":"A197","pred":"mondo_id","subj":"T197","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A198","pred":"mondo_id","subj":"T198","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of COVID-19 infection [55]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T181","span":{"begin":7,"end":10},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T182","span":{"begin":44,"end":45},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of COVID-19 infection [55]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T140","span":{"begin":0,"end":188},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of COVID-19 infection [55]."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T574","span":{"begin":117,"end":127},"obj":"GO:0042571"},{"id":"T575","span":{"begin":164,"end":172},"obj":"SP_7"},{"id":"T61832","span":{"begin":117,"end":127},"obj":"GO:0042571"},{"id":"T75491","span":{"begin":164,"end":172},"obj":"SP_7"}],"text":"CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of COVID-19 infection [55]."}